Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.56 AUD | -1.75% | -2.61% | -15.79% |
06-12 | Inoviq's Neuro-Net Technology Opens Opportunities for Alzheimer’s Diagnostics, Treatment; Shares Surge 20% | MT |
06-07 | Inoviq Requests Trading Halt | MT |
Business Summary
Number of employees: 15
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Telomerase Reverse Transcriptase
91.2
%
| 0 | 99.0 % | 0 | 91.2 % | +32.61% |
Molecular Nets
8.8
%
| 0 | 1.0 % | 0 | 8.8 % | +1,128.37% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
60.4
%
| 0 | 1.0 % | 0 | 60.4 % | +8,350.67% |
United States
39.6
%
| 0 | 99.0 % | 0 | 39.6 % | -42.49% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 06/11/16 |
Mark Edwards
DFI | Director of Finance/CFO | - | 01/11/22 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 19/09/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Williams
CHM | Chairman | 70 | 11-28 |
Philip Powell
BRD | Director/Board Member | 65 | 17/06/19 |
Geoff Cumming
BRD | Director/Board Member | - | 27/07/20 |
Robert Johnston
BRD | Director/Board Member | - | 17/06/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 92,018,702 | 79,458,065 ( 86.35 %) | 0 | 86.35 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.79% | 39.61M | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
+10.74% | 25.92B | |
-13.50% | 26.03B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B | |
-12.61% | 10.64B |
- Stock Market
- Equities
- IIQ Stock
- Company INOVIQ Ltd